Laboratory Equipment

Delray Beach, Fla. – September 25, 2026 -- The global liquid handling system market will grow from $5.26 billion in 2026 to $7.79 billion by 2031, expanding at a compound annual growth rate of 8.2%, according to a new report from MarketsandMarkets.

Automated systems and pipettes lead segment growth

Automated systems held the largest share of the market in 2025 and are projected to post the highest CAGR of 9.0% through 2031, as pharmaceutical and biotechnology laboratories shift from manual liquid transfer to robotic platforms for pipetting, dispensing, dilution and microplate handling. Within product categories, pipettes accounted for the largest 2025 share and are forecast to grow fastest at 9.5% CAGR, driven by adoption of electronic and multi-channel pipetting systems that integrate with laboratory information management systems (LIMS) and support nanoliter-scale dispensing for genomics and cell and gene therapy workflows.

Delray Beach – September 20, 2026 -- The global Laboratory Information Management System (LIMS) market is projected to grow from USD 3.26 billion in 2026 to USD 5.84 billion by 2031, a compound annual growth rate of 12.4%, according to MarketsandMarkets.

Rising test volumes force labs to digitize workflows

The US Centers for Disease Control and Prevention estimates that healthcare professionals order more than 14 billion laboratory tests annually across over 266,000 CLIA-certified laboratories nationwide. In India, the RMLIMS platform recorded complete blood count testing rise from 236,289 to 331,541 procedures between 2023 and 2025, while molecular testing volumes climbed from 728 to 1,236 over the same period.

Richmond – September 18, 2026 -- Alps Dx has named 26-year diagnostics industry veteran Pam Lacock as vice president of sales and opened a new 2,030-square-foot headquarters and manufacturing hub in Richmond, Virginia, as the company shifts from product development toward broader commercialization of its oral fluid testing platform.

Washington – September 18, 2026 -- The Association for Diagnostics & Laboratory Medicine (ADLM) has formally recommended that artificial intelligence tools used in clinical laboratories remain subject to the same validation, quality-system, and monitoring requirements that govern traditional laboratory testing under the Clinical Laboratory Improvement Amendments (CLIA). The recommendation was submitted in a comment letter responding to a federal request for information on potential updates to CLIA, the regulatory framework that has governed U.S. clinical laboratory testing since 1992.

Delray Beach, Fla. – September 17, 2026 -- The global pipette calibration services market is projected to more than double to USD 834.8 million by 2031 from USD 383.2 million in 2026, a 16.9% compound annual growth rate, according to MarketsandMarkets.

North America controls half of global demand as regulatory pressure mounts

North America held a 50.6% share of the pipette calibration services market in 2025, underpinned by dense pharmaceutical and biotechnology infrastructure, federal biomedical research funding, and strict laboratory equipment qualification requirements. Thermo Fisher Scientific, Eppendorf, and Sartorius operate significant service footprints across the region, supporting clinical labs, academic institutions, and drug manufacturers requiring traceable measurement accuracy.

Melbourne – September 16, 2026 -- IonOpticks has released Aurora Series 5, a nano-LC column platform that sustained over 10,000 unique protein identifications across more than 1,000 injections in extended laboratory testing, without a rise in backpressure beyond 1,400 runs.

Extended testing confirms durability across 1,400-plus injections on an 8-minute, 120-samples-per-day method

Testing was conducted on a Thermo Scientific Vanquish Neo UHPLC coupled to an Orbitrap Astral Zoom mass spectrometer. IonOpticks says the results allow laboratories to run nanoflow-level depth and sensitivity as a routine, high-throughput workflow rather than reserving it for select experiments.

Delray Beach, Fla. – September 16, 2026 -- The global cryovials market is projected to grow from $0.24 billion in 2026 to $0.31 billion by 2031, expanding at a compound annual growth rate of 5.5%, according to MarketsandMarkets.

Cell and gene therapy demand drives fastest-growing application segment

The cell and gene therapy segment is set to register the highest CAGR among applications at 8.0%, fueled by expanding commercialization of CAR-T cell therapies, stem cell treatments, and gene-modified therapies. These advanced therapies require secure cryogenic storage across collection, processing, manufacturing, transportation, and administration to preserve cell viability. Manufacturers scaling from clinical to commercial production are prioritizing sterile, barcoded cryovials with secure closure systems compatible with automated storage.

Delray Beach, Fla. – September 15, 2026 -- The global biological safety cabinet market is projected to grow from USD 0.26 billion in 2026 to USD 0.36 billion by 2031, a 6.6% CAGR, according to MarketsandMarkets.

Pharma investment and biosafety upgrades drive containment equipment demand

Expansion of drug discovery, biologics, cell and gene therapy, and vaccine development is pushing laboratories to replace aging cabinets with certified, higher-performance containment systems. Rising biosafety requirements for handling infectious agents and hazardous materials are accelerating both new installations and equipment upgrades across clinical, academic, and pharmaceutical labs.

Miami – September 9, 2026 -- BioEdge Research Labs has begun publishing batch-specific Certificates of Analysis (COAs) directly on its product pages, allowing laboratory customers to verify identity and purity data for the exact lot they receive rather than relying on aggregated supplier summaries.

Each lot now carries its own matched documentation

Instead of a single certificate applied across multiple production runs, every vial supplied by the Miami-based company is assigned a lot number tied to a corresponding COA, letting researchers cross-check the physical material against its specific record.

Independent labs handle identity and purity testing

The underlying analysis is conducted by a third-party laboratory rather than BioEdge itself, covering identity verification via mass spectrometry, purity assessment via high-performance liquid chromatography, and contaminant screening.

Statesville, N.C. – – September 15, 2026 -- Kewaunee Scientific Corporation (NASDAQ: KEQU) reported first-quarter fiscal 2027 sales of $66.3 million, down 6.7% from $71.1 million a year earlier, even as order backlog rose to $169.0 million from $165.9 million at the end of April.

Net earnings drop to $1.7 million on lower manufacturing volumes

Pre-tax earnings fell 34.7% to $2.56 million from $3.92 million in the prior-year quarter, while net earnings declined to $1.706 million from $3.093 million. Diluted earnings per share came in at $0.58, down from $1.04. EBITDA for the quarter totaled $4.525 million versus $6.32 million a year ago. Backlog, while up sequentially, remains well below the $205.0 million recorded on July 31, 2025.